A Study Examining Doses of Abiraterone Acetate in Adult Women With 21-Hydroxylase Deficiency

Phase 1

Completed

• Conditions: 21-hydroxylase Deficiency
• Interventions: Drug: Abiraterone acetate

• Registration Number: NCT01495910
• Lead Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Brief Summary

The purpose of this study is to determine the minimum dose of abiraterone acetate needed to decrease serum androstenedione to age-appropriate levels in premenopausal women on steroid replacement for classic 21-hydroxylase deficiency.

Detailed Description

This is a non-randomized (patients will not be assigned by chance to study treatments), open-label (patients will know the identity of study treatments), multiple-dose, intra-patient sequential dose-escalation study with a planned enrollment of approximately 10 patients. This study will consist of a screening period and a treatment period. Due to the intra-patient dose escalation, there will be multiple treatment periods consisting of 8 days each. A rest period of at least 7 days will separate each treatment period. Eligible patients will take study-defined replacement doses of hydrocortisone and fludrocortisone. Abiraterone acetate oral suspension will be administered in daily escalating doses from 100 mg to 500 mg. Patients will proceed to the next higher dose level when the majority of the treated patients have a reduction in the androstenedione level. Serial pharmacokinetic (study of what the body does to a drug) and pharmacodynamic (study of the effects of a drug on the body) samples will be collected at each treatment period as detailed in the protocol. All patients who receive at least 1 dose of abiraterone acetate will be analyzed for safety.

Study Timeline

• Study First Submitted: 2011-11-23
• Study Start: 2011-12
• Study First Submitted QC: 2011-12-16
• Study First Posted: 2011-12-20
• Primary Completion: 2013-02
• Study Completion: 2013-02
• Status Verified: 2014-02
• Last Update Submitted: 2014-02-27
• Last Update Posted: 2014-02-28

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Female
• Target Recruitment: 6

Inclusion Criteria

• Premenopausal women >=18 years of age.
• Must be receiving a hormonal contraceptive agent containing both estrogen and progesterone.
• Confirmed 21-hydroxylase deficiency by CYP21A2 genotype associated with classic congenital adrenal hyperplasia.
• Demonstrates a >=1.5 X ULN of morning serum androstenedione concentration while taking study-defined doses of hydrocortisone and fludrocortisone.
• No coexisting medical conditions in the opinion of the investigator that would preclude participation in the study.

Exclusion Criteria

• Current or history of active or chronic hepatitis, including symptomatic viral hepatitis A, B, or C.
• Any active infection.
• Evidence of active malignancy.
• Serious or uncontrolled co-existent non-malignant disease.
• Receiving systemic glucocorticoids for any reason other than for the treatment of 21-hydroxylase deficiency.
• Any disorders that require treatment with anticonvulsants.
• Patients of child-bearing potential who are not willing to use a method of birth control during the study and for 3 months after the end-of-study.
• Women who are pregnant or breast-feeding.
• Genotypes associated with non-classic congenital adrenal hyperplasia.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Abiraterone acetate	Abiraterone acetate	Abiraterone acetate oral suspension administered daily from study Day 1 to study Day 6 of each treatment period: the first dose level is 100 mg with escalating doses of 250 mg and 500 mg in subsequent treatment periods.

Primary Outcome Measures

Name	Time	Method
The minimum dose of abiraterone acetate required to decrease serum androstenedione to the age-appropriate range for adult women with 21-hydroxylase deficiency	Up to Day 7 of each treatment period.	Normalization or reduction of age-appropriate androstenedione levels will be determined by the mean of the androstenedione values measured on Study Days 6 and 7 of the treatment period.

Secondary Outcome Measures

Name	Time	Method
Maximum plasma concentration (Cmax) of abiraterone	Up to Day 8 of each treatment period.
Mean serum concentrations of androstenedione	Up to Day 8 of each treatment period.
Mean serum concentrations of 17-hydroxyprogesterone	Up to Day 8 of each treatment period.
Mean plasma concentrations of renin activity	Up to Day 8 of each treatment period.
Mean serum concentrations of testosterone	Up to Day 8 of each treatment period.
Urine concentrations of androsterone	Up to Day 8 of each treatment period.
Urine concentrations of etiocholanolone	Up to Day 8 of each treatment period.
Time to reach the maximum plasma concentration (tmax) of abiraterone	Up to Day 8 of each treatment period.
Area under the plasma concentration-time curve from time 0 to 24 hours postdose (AUC24) of abiraterone	Up to Day 8 of each treatment period.
Area under the plasma concentration-time curve from time 0 to time of the last quantifiable concentration (AUClast) of abiraterone	Up to Day 8 of each treatment period.
Time to last quantifiable plasma concentration (Tlast) of abiraterone	Up to Day 8 of each treatment period.
Elimination half-life associated with the terminal slope of the semilogarithmic drug concentration-time curve of abiraterone	Up to Day 8 of each treatment period.